Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-HBs persistence and hepatitis B challenge study in 6- to 7-year-old children previously vaccinated with hexavalent vaccine
2017-004069-29Phase 4Completed
- Sponsor
- Sanofi
- Start
- Oct 2018
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of hepatitis B vaccine recombinant in hepatitis B (HBV) (2 arms), sponsored by Sanofi. Primary endpoint: Individual anti-hepatitis B surface antibody concentrations. Started Oct 2018; status: completed.
02
Drugs
hepatitis B vaccine recombinant
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on 2017-004069-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004069-29.